NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma

Phase 2 Unknown 30 enrolled Shanghai Zhongshan Hospital

NaSingle-groupOpen-labelTreatment

Summary

The investigators will conduct a prospective, single-arm study to evaluate the safety and feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in patients with resectable esophageal squamous cell carcinoma (ESCC).

Timeline

Start: 2020-02-01
Primary completion: 2022-07-01
Completion: 2022-12-01

Outcome

Met primary endpoint

paper Our data showed the primary endpoints of safety and feasibility had been met. PMID 37488287 ↗

Publications

Yin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F, Gu J, Jiang T, Lin D, Huang Z, Du C, Wu K, Tan L, Zhou Q. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	—	—